Top 10 Selling Cancer Drugs

Roche’s Avastin is in 10th position. It is indicated for the treatment of colorectal cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, renal cell carcinoma and glioblastoma patients.  The total sale of this product is estimated at around $4.68 billion.

Next is Xtandi. Pfizer Inc. and Astellas Pharma Inc. are the makers of Avastin. This drug is used to treat patients with prostate cancer.  The total sale of this product is estimated at around $4.71 billion.

Roche’s Perjeta is in 8th position. It is indicated for HER2-positive breast cancer.  The total sale of Perjeta is estimated at around $4.73 billion.

Next is Johnson & Johnson’s Darzalex. It is indicated for the treatment of multiple myeloma. The total sale of Darzalex is estimated at around $4.91 billion.

Tecentriq is in 6th position. Novartis is the maker of this product. It is indicated to treat patients with urothelial carcinoma and non-small lung cancer. The total sale of Darzalex is estimated at around $5.53 billion.

Pfizer’s Ibrance is in 5th position. It is indicated for the treatment of metastatic breast cancer. The total sale of Ibrance is estimated at around $6.01 billion.

Next is Keytruda. Merck & Co. is the maker of this product. It is used for the treatment of patients with advanced melanoma, non-small cell lung cancer, head and neck squamous cell cancer.  The total sale of Darzalex is estimated at around $6.56 billion.

AbbVie’s Imbruvica is in 3rd position. It is indicated for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, waldenstrom macroglobulinemia. The total sale of this product is estimated at around $8.29 billion.

Next is Opdivo. Bristol-Myers Squibb and Ono Pharmaceutical are the makers of this product. It is indicated for the treatment of Non-small cell lung cancer, metastatic melanoma, renal cell carcinoma and classical Hodgkin lymphoma.  The total sale of this product is estimated at around $12.62 billion.

Celegene’s Revilimid is in 1st position. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. The total sale of this product is estimated at around $13.44 billion.